CL2021000355A1 - Inhibidores de ptpn11 - Google Patents
Inhibidores de ptpn11Info
- Publication number
- CL2021000355A1 CL2021000355A1 CL2021000355A CL2021000355A CL2021000355A1 CL 2021000355 A1 CL2021000355 A1 CL 2021000355A1 CL 2021000355 A CL2021000355 A CL 2021000355A CL 2021000355 A CL2021000355 A CL 2021000355A CL 2021000355 A1 CL2021000355 A1 CL 2021000355A1
- Authority
- CL
- Chile
- Prior art keywords
- ptpn11
- inhibitors
- compounds
- treatment
- ptpn11 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101150048674 PTPN11 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- DDZGQYREBDXECY-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyrazine Chemical class C1=CN=C2C=NNC2=N1 DDZGQYREBDXECY-UHFFFAOYSA-N 0.000 abstract 1
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 abstract 1
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a compuestos que son útiles como inhibidores de PTPN11 para el tratamiento o la prevención del cáncer y otras enfermedades mediadas por PTP. En el presente documento se divulgan compuestos nuevos y compuestos a base de pirazolopirazinas y su aplicación como productos farmacéuticos para el tratamiento de enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862717588P | 2018-08-10 | 2018-08-10 | |
US201862773921P | 2018-11-30 | 2018-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021000355A1 true CL2021000355A1 (es) | 2021-08-27 |
Family
ID=67766350
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000355A CL2021000355A1 (es) | 2018-08-10 | 2021-02-10 | Inhibidores de ptpn11 |
Country Status (22)
Country | Link |
---|---|
US (2) | US11104675B2 (es) |
EP (2) | EP4356973A3 (es) |
JP (2) | JP2021534124A (es) |
KR (1) | KR20210043569A (es) |
CN (1) | CN112601750B (es) |
AU (1) | AU2019319971A1 (es) |
BR (1) | BR112021002327A2 (es) |
CA (1) | CA3109181A1 (es) |
CL (1) | CL2021000355A1 (es) |
CO (1) | CO2021003074A2 (es) |
CR (1) | CR20210132A (es) |
DK (1) | DK3833670T3 (es) |
FI (1) | FI3833670T3 (es) |
IL (2) | IL307361A (es) |
LT (1) | LT3833670T (es) |
MX (1) | MX2021001608A (es) |
PE (1) | PE20211050A1 (es) |
PH (1) | PH12021550268A1 (es) |
PT (1) | PT3833670T (es) |
SG (1) | SG11202100199UA (es) |
TW (1) | TWI827646B (es) |
WO (1) | WO2020033828A1 (es) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
CA3094690A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CA3099151A1 (en) | 2018-05-02 | 2019-11-07 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of ptpn11 |
PT3833670T (pt) | 2018-08-10 | 2024-05-22 | Navire Pharma Inc | Derivados de 6-(4-amino-3-metil-2-oxa-8-azaspiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos similares como inibidores de ptpn11 (shp2) para o tratamento do cancro |
CA3113233A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
EP3947367A1 (en) | 2019-04-02 | 2022-02-09 | Array Biopharma, Inc. | Protein tyrosine phosphatase inhibitors |
EP3952998A1 (en) | 2019-04-08 | 2022-02-16 | Merck Patent GmbH | Pyrimidinone derivatives as shp2 antagonists |
WO2021061706A1 (en) | 2019-09-24 | 2021-04-01 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of making and using the same |
WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
JP2023530351A (ja) | 2020-06-18 | 2023-07-14 | レヴォリューション・メディスンズ,インコーポレイテッド | Ras阻害剤への獲得耐性を遅延させる、防止する、及び、治療する方法 |
WO2022060583A1 (en) | 2020-09-03 | 2022-03-24 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
CN117683049A (zh) | 2020-09-15 | 2024-03-12 | 锐新医药公司 | 作为ras抑制剂以治疗癌症的吲哚衍生物 |
AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
AU2022270116A1 (en) | 2021-05-05 | 2023-12-21 | Revolution Medicines, Inc. | Ras inhibitors |
EP4334324A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
TW202342043A (zh) | 2021-09-30 | 2023-11-01 | 美商納維爾製藥有限公司 | 使用ptpn11抑制劑及egfr抑制劑之組合療法 |
AU2022358413A1 (en) | 2021-09-30 | 2024-05-16 | Amgen Inc. | Combination therapy using substituted pyrimidin-4(3h)-ones and sotorasib |
TW202339748A (zh) * | 2021-10-06 | 2023-10-16 | 美商納維爾製藥有限公司 | 使用經取代之嘧啶-4(3h)-酮之治療方法 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023205794A1 (en) | 2022-04-22 | 2023-10-26 | Bristol-Myers Squibb Company | Combination therapy using a pyrimidone derivative as ptpn11 inhibitor and a pd-1/pd-l1 inhibitor and its use in the treatment of cancer |
WO2023205795A1 (en) * | 2022-04-22 | 2023-10-26 | Bristol-Myers Squbb Company | Combination therapy using a substituted pyrimidin-4(3h)-one and nivolumab as well as its use in the treatment of cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
JP2007523936A (ja) | 2004-02-27 | 2007-08-23 | エフ.ホフマン−ラ ロシュ アーゲー | ヘテロアリール縮合ピラゾロ誘導体 |
EP1732541A4 (en) | 2004-04-07 | 2008-03-05 | Takeda Pharmaceutical | CYCLIC COMPOUNDS |
ZA200704888B (en) | 2004-11-22 | 2009-02-25 | Vertex Pharma | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
GB0427604D0 (en) | 2004-12-16 | 2005-01-19 | Novartis Ag | Organic compounds |
GB0506147D0 (en) | 2005-03-24 | 2005-05-04 | Merck Sharp & Dohme | Therapeutic agents |
WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
CA2677651A1 (en) | 2007-02-15 | 2008-08-21 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
CA2738663A1 (en) | 2008-10-03 | 2010-04-08 | Schering Corporation | Spiro-imidazolone derivatives as glucagon receptor antagonists |
JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
KR20110049217A (ko) | 2009-11-04 | 2011-05-12 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
JP2011246389A (ja) | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ttk阻害作用を有する縮環ピラゾール誘導体 |
WO2012011592A1 (ja) * | 2010-07-23 | 2012-01-26 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
WO2013040527A1 (en) | 2011-09-16 | 2013-03-21 | Microbiotix, Inc. | Antimicrobial compounds |
WO2014047662A2 (en) | 2012-09-24 | 2014-03-27 | Whitehead Institute For Biomedical Research | Indazole derivatives and uses thereof |
AU2014256984B2 (en) | 2013-04-26 | 2019-02-14 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) |
US9850276B2 (en) | 2013-05-24 | 2017-12-26 | The Scripps Research Institute | Bidentate-binding modulators of LRRK2 and JNK kinases |
WO2015099481A1 (ko) | 2013-12-27 | 2015-07-02 | 주식회사 두산 | 유기 전계 발광 소자 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
KR101998435B1 (ko) | 2014-06-09 | 2019-07-09 | 주식회사 두산 | 유기 전계 발광 소자 |
SI3164380T1 (sl) * | 2014-07-03 | 2022-06-30 | Celgene Quanticel Research, Inc. | Inhibitorji lizin-specifične demetilaze-1 |
KR101708097B1 (ko) | 2014-10-22 | 2017-02-17 | 주식회사 두산 | 유기 전계 발광 소자 |
US10130629B2 (en) | 2015-03-25 | 2018-11-20 | Novartis Ag | Pharmaceutical combinations |
EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
CN107787323B (zh) * | 2015-06-19 | 2020-09-01 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
US10975080B2 (en) | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
US10858359B2 (en) | 2016-06-07 | 2020-12-08 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic ring derivatives useful as SHP2 inhibitors |
CN114057689A (zh) | 2016-06-14 | 2022-02-18 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
CA3030167A1 (en) | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
BR112019014527A2 (pt) * | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
KR102317480B1 (ko) | 2017-03-23 | 2021-10-25 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
TW201918260A (zh) | 2017-09-07 | 2019-05-16 | 美商銳新醫藥公司 | Shp2抑制劑組合物以及治療癌症的方法 |
WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS |
EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
SG11202002941WA (en) | 2017-10-12 | 2020-04-29 | Revolution Medicines Inc | Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors |
AU2018385713A1 (en) | 2017-12-15 | 2020-06-18 | Revolution Medicines, Inc. | Polycyclic compounds as allosteric SHP2 inhibitors |
US11426422B2 (en) | 2018-01-30 | 2022-08-30 | Research Development Foundation | SHP2 inhibitors and methods of use thereof |
WO2019158019A1 (zh) | 2018-02-13 | 2019-08-22 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
EP3759111A1 (en) | 2018-03-02 | 2021-01-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
CA3094690A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
US10561655B2 (en) | 2018-03-21 | 2020-02-18 | Synblia Therapeutics, Inc. | SHP2 inhibitors and uses thereof |
WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
BR112020020743A2 (pt) | 2018-04-10 | 2021-02-02 | Revolution Medicines, Inc. | composições de inibidor de shp2, métodos para tratar câncer e métodos para identificar um indivíduo com mutações de shp2 |
CA3099151A1 (en) | 2018-05-02 | 2019-11-07 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of ptpn11 |
CN115969853A (zh) | 2018-05-09 | 2023-04-18 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的新型杂环衍生物 |
WO2019233810A1 (en) | 2018-06-04 | 2019-12-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
JP7174143B2 (ja) | 2018-07-24 | 2022-11-17 | 大鵬薬品工業株式会社 | Shp2活性を阻害するヘテロ二環性化合物 |
PT3833670T (pt) | 2018-08-10 | 2024-05-22 | Navire Pharma Inc | Derivados de 6-(4-amino-3-metil-2-oxa-8-azaspiro[4.5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos similares como inibidores de ptpn11 (shp2) para o tratamento do cancro |
TWI825144B (zh) | 2018-08-10 | 2023-12-11 | 美商思達利醫藥公司 | 第二型轉麩醯胺酸酶(tg2)抑制劑 |
AR117183A1 (es) | 2018-11-30 | 2021-07-14 | Syngenta Crop Protection Ag | Derivados de tiazol microbiocidas |
TW202039496A (zh) | 2018-11-30 | 2020-11-01 | 美商默沙東藥廠 | 做為腺苷受體拮抗劑之9-經取代胺基***喹唑啉衍生物、醫藥組合物及其用途 |
EP4342473A3 (en) | 2018-11-30 | 2024-05-15 | GlaxoSmithKline Intellectual Property Development Limited | Compounds useful in hiv therapy |
CA3121504A1 (en) | 2018-11-30 | 2020-06-04 | Comet Therapeutics, Inc. | Pantetheine derivatives and uses thereof |
AR117200A1 (es) | 2018-11-30 | 2021-07-21 | Syngenta Participations Ag | Derivados de tiazol microbiocidas |
-
2019
- 2019-08-09 PT PT197591852T patent/PT3833670T/pt unknown
- 2019-08-09 JP JP2021506929A patent/JP2021534124A/ja not_active Ceased
- 2019-08-09 AU AU2019319971A patent/AU2019319971A1/en active Pending
- 2019-08-09 FI FIEP19759185.2T patent/FI3833670T3/fi active
- 2019-08-09 DK DK19759185.2T patent/DK3833670T3/da active
- 2019-08-09 IL IL307361A patent/IL307361A/en unknown
- 2019-08-09 EP EP24161326.4A patent/EP4356973A3/en active Pending
- 2019-08-09 US US16/536,923 patent/US11104675B2/en active Active
- 2019-08-09 KR KR1020217003134A patent/KR20210043569A/ko active IP Right Grant
- 2019-08-09 CA CA3109181A patent/CA3109181A1/en active Pending
- 2019-08-09 WO PCT/US2019/045903 patent/WO2020033828A1/en active Application Filing
- 2019-08-09 EP EP19759185.2A patent/EP3833670B1/en active Active
- 2019-08-09 LT LTEPPCT/US2019/045903T patent/LT3833670T/lt unknown
- 2019-08-09 PE PE2021000191A patent/PE20211050A1/es unknown
- 2019-08-09 IL IL280701A patent/IL280701B2/en unknown
- 2019-08-09 CN CN201980046071.6A patent/CN112601750B/zh active Active
- 2019-08-09 MX MX2021001608A patent/MX2021001608A/es unknown
- 2019-08-09 SG SG11202100199UA patent/SG11202100199UA/en unknown
- 2019-08-09 BR BR112021002327-5A patent/BR112021002327A2/pt unknown
- 2019-08-09 CR CR20210132A patent/CR20210132A/es unknown
- 2019-08-12 TW TW108128631A patent/TWI827646B/zh active
-
2021
- 2021-02-04 PH PH12021550268A patent/PH12021550268A1/en unknown
- 2021-02-10 CL CL2021000355A patent/CL2021000355A1/es unknown
- 2021-03-09 CO CONC2021/0003074A patent/CO2021003074A2/es unknown
- 2021-07-20 US US17/380,943 patent/US11945815B2/en active Active
-
2023
- 2023-08-17 JP JP2023132960A patent/JP2023144075A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CR20210132A (es) | 2021-07-20 |
PE20211050A1 (es) | 2021-06-04 |
US11945815B2 (en) | 2024-04-02 |
JP2021534124A (ja) | 2021-12-09 |
US20220041594A1 (en) | 2022-02-10 |
US20200048249A1 (en) | 2020-02-13 |
IL280701A (en) | 2021-03-25 |
CN112601750A (zh) | 2021-04-02 |
IL307361A (en) | 2023-11-01 |
IL280701B2 (en) | 2024-03-01 |
MX2021001608A (es) | 2021-07-15 |
AU2019319971A1 (en) | 2021-03-25 |
SG11202100199UA (en) | 2021-02-25 |
FI3833670T3 (fi) | 2024-05-21 |
EP3833670A1 (en) | 2021-06-16 |
KR20210043569A (ko) | 2021-04-21 |
CO2021003074A2 (es) | 2021-06-10 |
EP4356973A3 (en) | 2024-06-26 |
CA3109181A1 (en) | 2020-02-13 |
CN112601750B (zh) | 2023-10-31 |
EP4356973A2 (en) | 2024-04-24 |
WO2020033828A1 (en) | 2020-02-13 |
DK3833670T3 (da) | 2024-05-13 |
TWI827646B (zh) | 2024-01-01 |
EP3833670B1 (en) | 2024-04-17 |
PH12021550268A1 (en) | 2021-11-03 |
JP2023144075A (ja) | 2023-10-06 |
TW202019900A (zh) | 2020-06-01 |
US11104675B2 (en) | 2021-08-31 |
BR112021002327A2 (pt) | 2021-05-04 |
LT3833670T (lt) | 2024-06-25 |
PT3833670T (pt) | 2024-05-22 |
IL280701B1 (en) | 2023-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021000355A1 (es) | Inhibidores de ptpn11 | |
NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
ECSP21008112A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
ECSP16073190A (es) | Ciclopropilaminas como inhibidores de lsd1 | |
CO2017009298A2 (es) | Compuestos y composiciones de alfa-cinamida como inhibidores de hdac8 | |
CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
ECSP17070706A (es) | Inhibidores de bromodominio | |
CO2018004750A2 (es) | Composiciones para inhibir la actividad arginasa | |
CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
CL2019002304A1 (es) | Compuestos para el tratamiento del cáncer. | |
ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
BR112018077492A2 (pt) | métodos de tratamento de câncer de ovário | |
CO2017002191A2 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
DOP2022000082A (es) | Heterociclos bicíclicos como inhibidores de fgfr | |
ECSP17005635A (es) | Inhibidores de desmetilasa-1 específica a lisina | |
CR20150517A (es) | Inhibidores de la phd de 6-(5-hidroxi-1h-pirazol-1-il) nicotinamida | |
BR112019012062A2 (pt) | tratamento de uma doença do trato gastrointestinal com um inibidor de jak e dispositivos | |
ECSP20061378A (es) | COMPUESTOS DIÓLICOS DE AMINOPIRAZINA COMO INHIBIDORES DE PI3K-gamma | |
ECSP19057403A (es) | Usos terapéuticos de un polvo de insectos | |
CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
PE20170193A1 (es) | Derivados de 6-alquinil-piridina | |
CL2020001093A1 (es) | Proceso para preparar el benzotiofen-2-il boronato. | |
CO2023009803A2 (es) | Quinolinas y azaquinolinas como inhibidores de cd38 |